Repligen (NASDAQ:RGEN) Releases FY 2024 Earnings Guidance

Repligen (NASDAQ:RGEN) updated its FY 2024 earnings guidance on Wednesday. The company provided EPS guidance of 1.420-1.490 for the period, compared to the consensus EPS estimate of 1.460. The company issued revenue guidance of $620.0 million-$650.0 million, compared to the consensus revenue estimate of $635.6 million. Repligen also updated its FY24 guidance to $1.42-1.49 EPS.

Repligen Stock Performance

Shares of NASDAQ:RGEN traded up $0.74 on Friday, reaching $167.05. 454,984 shares of the company’s stock were exchanged, compared to its average volume of 538,521. The business’s 50-day moving average is $180.81 and its two-hundred day moving average is $174.09. The company has a quick ratio of 5.75, a current ratio of 6.35 and a debt-to-equity ratio of 0.26. Repligen has a fifty-two week low of $110.45 and a fifty-two week high of $211.13. The firm has a market capitalization of $9.33 billion, a price-to-earnings ratio of 668.23, a PEG ratio of 5.44 and a beta of 1.03.

Repligen (NASDAQ:RGEN) last issued its earnings results on Wednesday, May 1st. The biotechnology company reported $0.28 EPS for the quarter, missing analysts’ consensus estimates of $0.29 by ($0.01). The company had revenue of $151.31 million during the quarter, compared to analyst estimates of $150.06 million. Repligen had a net margin of 2.44% and a return on equity of 3.95%. The business’s revenue was down 17.1% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.64 earnings per share. As a group, equities research analysts forecast that Repligen will post 1.46 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on RGEN shares. JPMorgan Chase & Co. dropped their price objective on shares of Repligen from $230.00 to $200.00 and set an overweight rating on the stock in a report on Thursday. KeyCorp lifted their price target on Repligen from $210.00 to $220.00 and gave the company an overweight rating in a report on Thursday, February 15th. Finally, Stifel Nicolaus raised their target price on Repligen from $165.00 to $207.00 and gave the company a buy rating in a research report on Thursday, February 22nd. One analyst has rated the stock with a sell rating, one has issued a hold rating and eight have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Repligen has a consensus rating of Moderate Buy and a consensus price target of $197.75.

Insider Transactions at Repligen

In other Repligen news, COO James Bylund sold 4,373 shares of the company’s stock in a transaction dated Friday, February 23rd. The shares were sold at an average price of $198.08, for a total transaction of $866,203.84. Following the completion of the sale, the chief operating officer now directly owns 14,135 shares of the company’s stock, valued at $2,799,860.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. In other Repligen news, VP Ralf Kuriyel sold 3,517 shares of the firm’s stock in a transaction dated Monday, March 11th. The stock was sold at an average price of $193.73, for a total transaction of $681,348.41. Following the completion of the sale, the vice president now directly owns 24,260 shares in the company, valued at approximately $4,699,889.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, COO James Bylund sold 4,373 shares of the company’s stock in a transaction dated Friday, February 23rd. The shares were sold at an average price of $198.08, for a total value of $866,203.84. Following the completion of the transaction, the chief operating officer now owns 14,135 shares in the company, valued at approximately $2,799,860.80. The disclosure for this sale can be found here. Insiders have sold 25,597 shares of company stock valued at $5,039,532 over the last three months. Company insiders own 1.20% of the company’s stock.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.